Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00398632
Recruitment Status : Terminated (Unable to recruit subjects)
First Posted : November 14, 2006
Results First Posted : June 16, 2015
Last Update Posted : November 17, 2017
Eli Lilly and Company
Information provided by (Responsible Party):
Lorrin M Koran, Stanford University

November 10, 2006
November 14, 2006
April 19, 2015
June 16, 2015
November 17, 2017
November 2006
April 2009   (Final data collection date for primary outcome measure)
Global Clinical Impressions Improvement Score re Sexual Functioning [ Time Frame: baseline and last observation (4 subjects at end of week 12, 2 subjects at end of week 6) ]
The GCI-I score is a global clinical impression score regarding a patient's symptom severity change rated by the treating clinician. The score can be 0 (not assessed), 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) or 7 (very much worse). In this study clinicians made ratings based on interviewing the patient and reviewing the patient's self ratings on the the Arizona Sexual Experiences Scale (ASEX). No formal cut point scores on the ASEX were established. The ASEX is a 5-item slef rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach organism, and satisfaction from orgasm. Each item is rated from 1 to 6 (total scores from 5 to 30), with higher scores indicating greater sexual dysfunction.
  • Arizona Sexual Experience Scale
  • Inventory of Depressive Symptomatology, Clinical Rated
  • Clinical Global Impressions, Severity and Improvement
Complete list of historical versions of study NCT00398632 on Archive Site
Count of Patients With Remission of Depressive Symptoms According to the Inventory for Depressive Symptomology-Clinician Rated (IDS-C) at End of Study [ Time Frame: Last observation (4 subjects at end of week 12, 2 subjects at end of week 6) ]
The IDS-C is a 30-item inventory designed to assess the severity of depressive symptoms. Scale range minimum = 0 / maximum = 84. Higher values are considered to be worse outcomes. Scores less than or equal to 6 indicated remission in this study.
Not Provided
Not Provided
Not Provided
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction
Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs). The hypotheses of this study are that:1. subjects with major depression or dysthymia who are being treated with an SSRI and experiencing treatment-related sexual dysfunction will experience less sexual dysfunction if they are switched to duloxetine, and 2. they will experience either improved antidepressant response or no loss of antidepressant response.
In this study, subjects suffering from depression or dysthymia and experiencing treatment-emergent sexual dysfunction from an SSRI are switched from their SSRI to duloxetine to determine whether or not they experience improved sexual function and equal or improved antidepressant response. Study subjects are assigned to receive open label duloxetine for 12 weeks at either 60mg per day or 120mg per day after discontinuing their current antidepressant
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Drug: Duloxetine
dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
Other Name: Cymbalta
Experimental: Duloxetine
Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
Intervention: Drug: Duloxetine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2009
April 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria::

  • age 18 - 65 inclusive
  • able to read and understand informed consent
  • informed consent given
  • currently being treated with an SSRI for depression or dysthymia
  • currently suffering from treatment-emergent sexual dysfunction attributable to the SSRI
  • have normal safety lab values at screen
  • if currently taking medication to improve sexual performance, willing to discontinue the drug for the duration of the study
  • female subjects of child bearing age need to use an acceptable form of birth control throughout the study

Exclusion Criteria:- being pregnant, breastfeeding, or planning to become pregnant within 4 months

  • suffering from psychotic, substance abuse, bipolar, or organic mental disorder, OCD, panic disorder, or personality disorder severe enough to interfere with study participation
  • suffer from an unstable or serious medical disorder
  • having a medical disorder that could be the cause of the sexual dysfunction
  • taking a medication that is metabolized by hepatic enzyme CYP2D6
  • having used a MAOI within 15 days of proposed start of duloxetine treatment
  • having a known hypersensitivity to duloxetine or any of its ingredients
  • having taken viagra or related drug within 3 months prior to starting SSRI treatment
  • requiring ongoing treatment with a mood stabilizer (anticonvulsant) or antipsychotic medication
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Lorrin M Koran, Stanford University
Stanford University
Eli Lilly and Company
Principal Investigator: Lorrin M Koran Stanford University
Stanford University
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP